Skip to main
Telehealth Wolverine

An instructional scroll of the research on the Wolverine blend — BPC-157 and TB-500 read as two mechanisms set side by side, with the regulatory and compounded-access record carved into the closing register.

Every study and FDA page cited here

BPC-157 TB-500 references: Which sources hold the facts?

Each bracketed number leads to a full study. The FDA records appear below too.

Return to the findingsRead the FDA facts

The BPC-157 TB-500 reference list names every source

Where did the facts come from? Each bracketed number beside a BPC-157 or TB-500 claim matches a full source below. The list includes studies, reviews, and FDA records. The FDA entries link straight to the agency pages.

Each paper tells you which single substance was tested. No published controlled study tested the pair [9]. That is why no blend trial appears. Use the Wolverine blend references to check a claim. The full title and link sit beside each numbered source.

  1. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. ↗
  2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
  3. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. ↗
  4. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. ↗
  5. Cassimeris L, Safer D, Nachmias VT, Zigmond SH. Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes. J Cell Biol. 1992;119(5):1261-1270. ↗
  6. Tokura Y, et al. Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts. J Biochem. 2011;149(1):43-48. ↗
  7. Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. ↗
  8. Editorial synthesis: no peer-reviewed controlled study has administered BPC-157 and TB-500 in combination or defined a synergy ratio, dose, or endpoint. Basis: the absence of any combination study across the cited BPC-157 and thymosin beta-4 literature, including the 2025 BPC-157 systematic review (ref. 10), which makes no mention of TB-500 or combination use. ↗
  9. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. ↗
  10. Compositional and identity basis for the BPC-157 + TB-500 blend: BPC-157 is a 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV, ~1419.5 Da); TB-500 is the synthetic Ac-LKKTETQ heptapeptide (~889 Da), residues 17-23 of thymosin beta-4, and most efficacy data attributed to 'TB-500' were generated with full-length thymosin beta-4. The blend has no single CAS/MW and no standardized ratio. Identity of the TB-500 fragment established in Esposito S, et al., Drug Test Anal. 2012 (ref. 7); the actin-binding fragment relationship in Irobi E, et al., EMBO J. 2004 (ref. 3). ↗
  11. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. ↗
  12. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. ↗
  13. Pharmacokinetic and dose-context basis: BPC-157 elimination half-life reported under 30 minutes in a rat/dog PK study, and rodent doses commonly expressed per body weight (frequently ~10 microg/kg; gastric-ulcer cytoprotection at 400-800 ng/kg). Thymosin beta-4 dose-response in a rat embolic-stroke model spanned 2-18 mg/kg intraperitoneal, with 18 mg/kg giving no benefit (non-monotonic). Compiled in the audited Wolverine research corpus (dosage_research_context); thymosin beta-4 stroke dose-response per Morris DC, et al., Neuroscience. ↗
  14. World Anti-Doping Agency. The Prohibited List. BPC-157 is listed under category S0 (non-approved substances); thymosin beta-4 / TB-500 falls under prohibited peptide and tissue-repair categories. Prohibited at all times, in and out of competition. ↗
  15. Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
  16. Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
  17. Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
  18. et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗